| Microsampling: considerations for its use in pharmaceutical drug discovery and development |
13 |
| Capillary blood microsampling to determine serum biopharmaceutical concentration: Mitra((R)) microsampler vs dried blood spot |
13 |
| Microsampling for quantitative bioanalysis, an industry update: output from an AAPS/EBF survey |
12 |
| Analytical techniques for metabolomic studies: a review |
9 |
| Direct quantitation of therapeutic antibodies for pharmacokinetic studies using immuno-purification and intact mass analysis |
9 |
| Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood |
9 |
| Development and full validation of an innovative HPLC-diode array detection technique to simultaneously quantify lacosamide, levetiracetam and zonisamide in human plasma |
8 |
| LC-HRMS quantitation of intact antibody drug conjugate trastuzumab emtansine from rat plasma |
8 |
| Next-generation biomarker discovery in Alzheimer's disease using metabolomics - from animal to human studies |
8 |
| Top-down LC-MS quantitation of intact denatured and native monoclonal antibodies in biological samples |
8 |
| Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review |
8 |
| A validated UPLC-MS/MS method for flibanserin in plasma and its pharmacokinetic interaction with bosentan in rats |
7 |
| High sensitivity methods to quantify chloroquine and its metabolite in human blood samples using LC-MS/MS |
7 |
| Coated blade spray: shifting the paradigm of direct sample introduction to MS |
7 |
| Supercritical fluid chromatography: a promising alternative to current bioanalytical techniques |
6 |
| Targeting human urinary metabolome by LC-MS/MS: a review |
6 |
| Steroidomics for highlighting novel serum biomarkers of testosterone doping |
6 |
| Proposed selection strategy of surrogate matrix to quantify endogenous substances by Japan Bioanalysis Forum DG2015-15 |
6 |
| A UHPLC-MS/MS method for the quantification of 9-tetrahydrocannabinol and cannabidiol in decoctions and in plasma samples for therapeutic monitoring of medical cannabis |
6 |
| Nonclinical immunogenicity risk assessment of therapeutic proteins |
6 |
| A volumetric absorptive microsampling LC-MS/MS method for five immunosuppressants and their hematocrit effects |
6 |
| Immunogenicity testing of therapeutic antibodies in ocular fluids after intravitreal injection |
6 |
| Review of approaches and examples for monitoring biotransformation in protein and peptide therapeutics by MS |
6 |
| Protein quantification by LC-MS: a decade of progress through the pages of Bioanalysis |
6 |
| Drug monitoring by volumetric absorptive microsampling: method development considerations to mitigate hematocrit effects |
6 |
| Neuro biomarker levels measured with high-sensitivity digital ELISA differ between serum and plasma |
6 |
| Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls |
5 |
| Quantitation of intact monoclonal antibody in biological samples: comparison of different data processing strategies |
5 |
| Clinical biomarker validation |
5 |
| Application of Mitra((R)) microsampling for pharmacokinetic bioanalysis of monoclonal antibodies in rats |
5 |
| GCC Consolidated Feedback to ICH on the 2019 ICH M10 Bioanalytical Method Validation Draft Guideline |
5 |
| What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? |
5 |
| A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers |
5 |
| Quantification of eicosanoids and their metabolites in biological matrices: a review |
5 |
| A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III |
5 |
| Validation of methods for determining pediatric midazolam using wet whole blood and volumetric absorptive microsampling |
5 |
| Development of an IL-6 point-of-care assay: utility for real-time monitoring and management of cytokine release syndrome and sepsis |
5 |
| A novel LC-MS/MS assay to quantify dermatan sulfate in cerebrospinal fluid as a biomarker for mucopolysaccharidosis II |
5 |
| An ultrasensitive UPLC-MS/MS assay for the quantification of the therapeutic peptide liraglutide in plasma to assess the oral and nasal bioavailability in beagle dogs |
5 |
| Evaluation of the Mitra microsampling device for use with key urinary metabolites in patients with Alkaptonuria |
5 |
| Very complex internal standard response variation in LC-MS/MS bioanalysis: root cause analysis and impact assessment |
5 |
| Quantification of phenolic acid metabolites in humans by LC-MS: a structural and targeted metabolomics approach |
5 |
| Synthetic cannabinoids in biological specimens: a review of current analytical methods and sample preparation techniques |
5 |
| Immunogenicity of therapeutic protein products: current considerations for anti-drug antibody assay in Japan |
5 |
| Drug exposure during pregnancy: analytical methods and toxicological findings |
5 |
| Surface plasmon resonance as a tool for ligand-binding assay reagent characterization in bioanalysis of biotherapeutics |
5 |
| Immunogenicity of antibody-drug conjugates: observations across 8 molecules in 11 clinical trials |
4 |
| Effective presentation of immunogenicity risk assessments and related data in regulatory dossiers |
4 |
| A novel HPLC-DAD method for simultaneous determination of febuxostat and diclofenac in biological samples: pharmacokinetic outcomes |
4 |
| Sensitive and robust LC-MS/MS analysis of digoxin in human plasma through optimization of in-source adduct formation |
4 |
